Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Breast Neoplasms

Treatments: Drug: exemestane; Drug: Fulvestrant; Drug: CP-751,871

Study type: Interventional

Funder types: Industry

Identifiers

NCT00372996

A4021004

2006-005573-21 (EudraCT Number)

Details and patient eligibility

About

To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

Enrollment: 219 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer
• HbA1c <5.7%

Exclusion criteria

• Previous treatment for advanced disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

219 participants in 2 patient groups

1

Experimental group

Description:

CP-751,871 + exemestane Treatment until progression or toxicity

Treatment:

Drug: exemestane

Drug: Fulvestrant

Drug: exemestane

Drug: CP-751,871

2

Active Comparator group

Treatment:

Drug: exemestane

Drug: exemestane